Resolve Nanotherapeutics

Revolutionizing acute infection treatment

Our Mission

Resolve Nanotherapeutics is dedicated to innovating and developing cutting-edge technology to treat serious infections. Our focus lies in targeted therapies that significantly improve patient outcomes.

Learn more
rntx stock image 1

Acute infections are a global emergency!

Acute bacterial infections like pneumonia and peritonitis are leading global killers
and our current arsenal of antibiotics may no longer work within the next 20 years due to the rise of antibiotic resistance.

mortality rate within 1-month
15- %
readmission or death within 1 year
0 %
leading cause of death annually (14%)
0 rd

Every breakthrough starts with a bold question: What if acute infections could be disarmed without feeding resistance? We address this challenge head-on by combining innovative genetic insights with a host-directed therapeutic strategy and precision RNA delivery to usher in a new era of critical care medicine.

Genetic Clues

Human genetic data revealed fresh therapeutic targets to treat acute infections—opening the door for therapeutics beyond conventional antibiotics.

Resistance-Free

A host focused therapy with broad-spectrum function that is not susceptible to development of resistance by bacteria.

LNP RNA Systems

Lipid nanoparticle (LNP) RNA systems are a clinically validated drug delivery platform that can be rapidly developed with new payloads that address unmet clinical needs.

Learn how our innovative approach is redefining treatment →

Learn More

Get Involved Today

Join us in making a difference. Your support helps drive breakthroughs in nanotherapeutics for those in need.

Contact us

Jim Russell, MD. - Co-Founder and Board Chair

Dr. Russell has 43 years experience doing research on severe infections. His main focus has been discovery of biomarkers and novel therapeutics.  Dr. Russell has pivoted to research on community-acquired pneumonia (CAP), the commonest cause of sepsis, a more homogeneous condition than sepsis for mechanistic and drug discovery.  He was a founder of Sirius Genomics and Cyon Therapeutics. He is the #1 global expert in septic shock research (Expertscape; 326 publications. H index 93). He has led trials in septic shock and COVID-19, and during and after the COVID pandemic he secured $7M CIHR, St. Paul’s Foundation and other funding for the CAPtivate program (27 publications) and has raised $23.5M as a co-investigator. He has extensive experience with murine and human sepsis and was a co-discoverer of the central role of PCSK9 in severe infections.

This will close in 0 seconds

Ehsan Ansari Dezfouli, PhD. - Senior Scientist, Mitacs Postdoctoral Fellow

Dr. Dezfouli is a nanomedicine researcher with over 10 years of experience in formulation and drug development, having worked on LNP mRNA COVID-19 vaccines and in vivo CAR-T applications. He also has over 5 years of industrial experience in nanomedicine development and is currently working as a post-doctoral fellow in the labs of Dr. Russell and Cullis to develop LNP RNA drugs for severe acute infections. Dr. Dezfouli is working as lead scientist in the lab.

This will close in 0 seconds

Cedric Brimacombe, PhD. - Co-Founder, VP BD

Dr. Brimacombe is a synthetic biologist with extensive experience in infectious disease and bacterial and fungal genetics and has worked as a lead researcher in both Academia and Industry for over 15 years. In 2017 he established the Molecular Biology lab at Renaissance BioScience and ran a successful program of RNAi research and development for over 4.5 years as the molecular scientific lead. He also made key contributions to several widely sold industrial yeast products. He later moved to Polymorphic BioScience Inc. in a Business Development position working in the LNP space and has played a leading role in acquiring ~$43 million in government grants for academic and industrial projects. Further, he has lead efforts in developing, funding, and initiating several new projects in LNP RNA space, and manages multiple partnerships and smaller research groups.

This will close in 0 seconds

Pieter Cullis, PhD. - Co-founder

Dr. Cullis has over 40 years of experience in drug development and commercialization. Most notably, Dr. Cullis played an essential role in driving the creation of LNP technology, an essential component of the FDA-approved drugs Onpattro® and Comirnaty® (the Pfizer/BioNTech SARS-CoV-2 vaccine) for which he has received many prestigious awards. Dr. Cullis has extensive experience bringing drugs from concept to clinical application using lipid-based carriers. To this end, he has co-founded more than 12 companies including Acuitas Therapeutics, Precision Nanosystems, Integrated Nanotherapeutics, and NanoVation Therapeutics, among others. He provides strong leadership and advisory experience. Dr. Cullis has played a key role in bringing 5 nanomedicines from basic research labs to clinical application and provides unmatched guidance and a vast network in this regard.

This will close in 0 seconds

Evan Haney, PhD - Director of Operations

Dr. Haney is a biochemist with over 20 years experience across the fields of microbiology, immunology and structural biology and has worked in both academia and industry settings developing novel anti-infective agents and molecular diagnostics assays. In 2021, he joined Asep Medical Inc. as Chief Scientific Officer where he led teams designing novel peptide-based therapeutics targeting bacterial biofilms and spearheaded the development of an innovative blood-based diagnostic test for sepsis. He is a highly productive scientist with over 50 publications, is an inventor on three patents and has given numerous presentations at conferences around the world.

This will close in 0 seconds

Scroll to Top